American Society of Hematology

Afternoon Symposia

The following symposia took place prior to the 2017 ASH Annual Meeting. View the FSS Guidelines to learn about hosting a symposium in 2018.

Friday, December 8, 12:30 p.m. - 4:30 p.m.

Friday Satellite Symposia (FSS) will take place on Friday, December 8, 2017, preceding the ASH annual meeting. ASH appreciates its corporate and nonprofit partners for their participation in FSS. The Society values its partnerships and the supportive role that members of this community play in an effort to provide hematologists with quality educational programs.

Program Chair:

Mehdi Hamadani, MD, Medical College of Wisconsin
Milwaukee, WI

A Brave New World: The Clinical Management of Bone Marrow Failure and Myeloid Malignancy in a Time of Personalized Therapy

Friday, December 8, 2017, 12:30 p.m. - 4:30 p.m.
Marriot Marquis Atlanta, A703-A704

This program is sponsored by Cleveland Clinic and supported by Achillion Pharmaceuticals, Celgene Corporation, Geron Corporation, Incyte Corporation, Jazz Pharmaceuticals, Karyopharm Therapeutics, Onconova Therapeutics, Inc. and Takeda Oncology.

The Cleveland Clinic Taussig Cancer Institute and AA & MDS International Foundation join together to present this symposium. This CME-certified activity will provide an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with AA, PNH, MDS, and AML. The overall goal of the program is to bring together leaders in disease research and clinical practice to explore solutions to improving the care of these patient populations.

Chairs:

Hetty E. Carraway, MD, MBA
Cleveland Clinic
Cleveland, OH

Sudipto Mukherjee, MD, PhD, MPH
Cleveland Clinic
Cleveland, OH

Speakers:

Corey S. Cutler, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Gerard Socie, MD, PhD
Hematology Transplantation
Paris, France

Valeria Santini, MD
University of Florence
Florence, Italy

Laura C. Michaelis, MD
Medical College of Wisconsin
Milwaukee, WI

Mark J. Levis, MD, PhD
Johns Hopkins University
Baltimore, MD

Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center
Houston, TX

Contact:

Ronna Romano
Cleveland Clinic
Phone: 216-448-8688
Email: romanor@ccf.org

back to top

A Master-Class on Building Better Therapy for AML: Making the Most of an Increasing Number of Innovative Options

Friday, December 8, 2017, 12:30 p.m. - 4:30 p.m.
Georgia World Congress Center, Bldg B- Lvl 5- Murphy BR 1-2

This program is sponsored by PeerView Institute for Medical Education and supported by AbbVie, Actinium Pharmaceuticals, Agios Pharmaceuticals, Astellas Scientific & Medical Affairs, Inc., Celgene Corporation, and Jazz Pharmaceuticals, Inc.

The approach to managing acute myeloid leukemia (AML) is poised to make a leap into an era where multiple novel options may be available to treat a range of complex AML presentations. Hematology-oncology professionals can expect better therapy and improved outcomes as new science continues to show the clinical potential of novel agent classes (including targeted agents, newer antibodies, immune-based options, and newer cytotoxics) when used in conjunction modern prognostic advances such as cytogenetic and molecular testing.

This PeerView Live CME-certified AML event - conducted in a "Master Class" case format - will feature multiple expert perspectives on the modern AML treatment paradigm and illustrate how professionals can navigate an increasingly complex therapeutic landscape as more effective strategies are validated in patients with a variety of AML presentations, including patients with FLT3 or IDH mutant disease, elderly individuals, secondary AML, or those eligible for clinical trial-based treatment with antibodies or immunotherapy. This symposium will offer a deep dive into the science that is driving the rapidly emerging new era in AML patient care.

Chair:

Harry P. Erba, MD, PhD
University of Alabama at Birmingham
Birmingham, AL

Speakers:

Naval Daver, MD
The University of Texas MD Anderson Cancer Center
Houston, TX

Amir T. Fathi, MD, MD, BS
Massachusetts General Hospital Cancer Center, Harvard Medical School
Boston, MA

Stephen A. Strickland, MD, MSCI
Vanderbilt University Medical Center
Nashville, TN

Michael R. Savona, MD
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Nashville, TN

Contact:

Cassie Rametta
PeerView Institute for Medical Education
Phone: 1-877-833-6141
Email: live@peerview.com

back to top

Addressing Current Questions and Controversies in the Management of Lymphoma and Chronic Lymphocytic Leukemia (Part 1 of 2)

Friday, December 8, 2017, 12:30 p.m. - 4:30 p.m.
Marriot Marquis Atlanta, Marquis C-D

This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP/Acerta Pharma, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics, and Takeda Oncology.

This activity, the first of a proposed two-part series, will attempt to address many of the most common practical issues faced by clinicians managing patients with Hodgkin and non-Hodgkin lymphomas as well as chronic lymphocytic leukemia (CLL). To accomplish this goal, prior to the event RTP will recruit five general hematologic oncologists to serve as the project’s planning committee. These individuals will participate in several planning sessions intended to tease out the patient scenarios, management concerns, and available data sets that pose the greatest challenge to their clinical decision-making. Utilizing this information as the basis for the agenda, the meeting, which will feature five renowned investigators as the program faculty, will employ a blend of short didactic presentations, interactive audience polling utilizing networked tablets, and extensive moderated panel discussion to provide perspectives on new and emerging research and address many of the real-world concerns voiced by the planning committee members. A video-recorded capture of the program will be distributed as an enduring CME activity to deliver the valuable and practical information that emerges to a larger worldwide audience.

Chair:

Neil Love, MD
Research To Practice
Miami, FL

Speakers:

Craig H. Moskowitz, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Jonathan W. Friedberg, MD
University of Rochester
Rochester, NY

Martin Dreyling, MD, PhD
Klinikum Der Universitaet Muenchen-Campus Grosshadern
Munich, Germany

Owen A. O’Connor, MD, PhD
Columbia University Medical Center
New York, New York, 

Laurie H. Sehn, MD,MPH
British Columbia Cancer Agency
Vancouver, BC, Canada

Contact:

Sylvia Eriksen
Research To Practice
Phone: 305-377-2828
Email: seriksen@researchtopractice.com

back to top

Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With GvHD

Friday, December 8, 2017, 12:30 p.m. - 4:30 p.m.
Georgia World Congress Center, Bldg A- Lvl 4- A402-A403

This program is sponsored by Physicians' Education Resource and supported by Incyte Corporation.

Participants of this educational curriculum will be brought up to date on the most recent clinical advances in novel diagnostic, therapeutic, and patient counseling strategies that will potentially impact treatment and management of patients with graft-versus host disease. The symposium is designed to educate audiences in an innovative, engaging format and will include a mix of didactic lecture, case-studies that reflect challenges among community hematologists when deciding clinical trial options for patients, panel discussion, and Q&A. The program is designed to be fast-paced and highly interactive between faculty and audience. Case-studies and panel discussions will be used by the chair to challenge faculty on their treatment decisions and to give the opportunity for the audience to reflect on best practices and their own clinical decisions for higher educational engagement.

Chair:

John F DiPersio, MD, PhD
Washington University School of Medicine
Saint Louis, MO

Speakers:

Karl Peggs, MBBChir
University College London Hospitals
London, United Kingdom

Stefanie Sarantopoulos, MD, PhD
Dept. of Medicine, Div. of Hematological Malignancies & Cellular Therapy, Duke University Medical Center
Durham, NC

Contact:

Stephanie Neumann
Physicians' Education Resource, LLC (PER)
Phone: 609-716-7777
Email: sneumann@gotoper.com

back to top

Anticoagulation: Applying Innovation in Clinical Practice

Friday, December 8, 2017, 12:30 p.m. - 4:30 p.m.
Marriot Marquis Atlanta, Marquis A

This program is sponsored and supported by Thrombosis Research Institute.

In this symposium, a renowned international faculty will provide contemporary narratives on:

  • Venous thromboembolism (VTE) – the relationship between patient characteristics, the clinical presentation of VTE, the choice of anticoagulation/antithrombotic therapy (over the first 3 months of care and extended treatment), and outcomes
  • Burden of thrombosis in cancer patients (including VTE, arterial events, and bleeding-associated events with anticoagulation) and the prevention and treatment of cancer-associated thrombosis
  • Anticoagulation strategies in patients with atrial fibrillation (AF)
  • The utility of anticoagulation in patients with coronary artery disease

Each presentation will review and provide perspectives on:

  • The latest evidence from randomized controlled trials
  • Data from ongoing registries
  • Recommendations from the most recent clinical guidelines

Time will be dedicated to the discussion of some of the most challenging clinical scenarios using case histories to guide the debate and key-pad voting to canvass the views of the audience.

Chair:

Ajay K. Kakkar, MB, PhD
University College London
London, United Kingdom

Speakers:

A. John Camm, QHP, MD
St. George’s University of London and St. George’s Hospital
London, United Kingdom

Keith A. Fox, MBBS
The University of Edinburgh
Edinburgh, United Kingdom

Ajay K. Kakkar, MB, PhD
University College London
London, United Kingdom

Howard A. Liebman, MD
University of Southern California
Los Angeles, CA

Alexander G. Turpie, MD
Hamilton Health Sciences
Hamilton, Canada

Jeffrey I. Weitz, MD
McMaster University, and the Thrombosis and Atherosclerosis Research Institute
Hamilton, ON, Canada

Contact:

Kim R. Page
University of Kentucky
Phone: 859-218-0340
Email: kim.page@uky.edu

back to top

Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical Experience

Friday, December 8, 2017, 12:30 p.m. - 4:30 p.m.
Georgia World Congress Center, Bldg B- Lvl 3- B308-B309

This program is sponsored by Physicians' Education Resource, LLC and supported by Juno Therapeutics, Inc.

Chimeric antigen receptor (CAR) T cells have recently emerged as a novel therapeutic approach, yielding complete responses even in heavily pretreated patients with leukemia, lymphoma, and myeloma. This new therapeutic modality, nevertheless, has created a need to inform and educate physicians as they incorporate the use of CAR T cells. To address this educational need, this symposium will feature internationally renowned experts in hematology/oncology who will discuss the science and clinical data underlying CAR T-cell therapy, provide practical advice for incorporating CAR T cells into treatment algorithms for patients with lymphoid malignancies, and share proactive measures to manage adverse events. Extended question-and-answer sessions will also provide opportunities for interaction between the expert faculty and participants.

Chair:

David G. Maloney, MD, PhD
University of Washington
Seattle, WA

Speakers:

Stephen J. Schuster, MD
University of Pennsylvania
Philadelphia, PA

Jeremy S. Abramson, MD
Massachusetts General Hospital
Boston, MA

James N. Kochenderfer, MD
National Cancer Institute
Bethesda, MD

Contact:

Kirby Beneville
Physicians' Education Resource, LLC
Phone: 214-906-6183
Email: kbeneville@gotoper.com

back to top

Exploring New Strategies in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Friday, December 8, 2017, 12:30 p.m. - 4:30 p.m.
Hyatt Regency Atlanta, Centennial I

This program is sponsored by prIME Oncology and supported by Takeda Oncology.

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) has traditionally been a difficult disease to treat as this ALL subtype does not respond well to standard chemotherapy regimens and older patients with Ph+ ALL often do not respond well to intensive chemotherapy regimens. Recent advances in molecular diagnostic techniques, as well as newer targeted therapies, have altered the treatment landscape and allow clinicians a tool to personalize therapy. This symposium provides an in depth exploration of these topics, including discussion of non-intensive vs aggressive initial therapy, how deep sequencing can influence treatment decisions, and the role of stem cell transplantation in the treatment of Ph+ ALL.

Chair:

Hagop M. Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Houston, TX

Speakers:

Elias J. Jabbour, MD
The University of Texas MD Anderson Cancer Center
Houston, TX

Sergio A. Giralt, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Giovanni Martinelli, MD
University of Bologna
Bologna, Italy

Hugues De Lavallade
Kings College Hospital NHS Foundation Trust
London, United Kingdom

back to top

Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions

Friday, December 8, 2017, 12:30 p.m. - 4:30 p.m.
Marriot Marquis Atlanta, Atrium A

This program is sponsored by the International Myeloma Foundation, Clinical Care Options, LLC, and Annenberg Center for Health Sciences at Eisenhower and supported by Amgen, Inc., The Binding Site, Celgene Corporation, Janssen Scientific Affairs, LLC Karyopharm Therapeutics Inc., and Takeda Oncology.

This year’s International Myeloma Foundation–sponsored symposium will provide a review of emerging data and how those data can be integrated into practice to address current clinical questions and challenges in caring for patients with multiple myeloma (MM). Symposium participants will enjoy an engaging program with lively debate among internationally renowned experts. Throughout the symposium, participants will be presented with multiple case challenges followed by management questions. After the audience votes on a case, the panelists will review the available data and present participants with their treatment recommendations for that case. The panel will then discuss and debate each case in the symposium and will defend and provide a rationale for their treatment recommendations. Topics will include:

  • Accurately Diagnosing MM: When Should Systemic Myeloma Treatment Be Initiated?
  • Individualized Approaches to Treatment Selection for Induction Therapy
  • Transplant, Consolidation, and Maintenance: The Role of MRD in Monitoring
  • Therapeutic Strategies After First Relapse Following Initial Therapy
  • Current and Future Options for Therapy in Patients With Late Relapse
  • Review of a 2018 Treatment Algorithm for MM

Chair:

Brian G.M. Durie, MD
Cedars-Sinai Outpatient Cancer Center
Los Angeles, CA

Speakers:

Jesús F. San-Miguel
Clínica Universidad de Navarra-CIMA, IDISNA
Pamplona, Spain

S. Vincent Rajkumar, MD
Mayo Clinic
Rochester, MN

Bruno Paiva, PhD
Clinica Universidad de Navarra
Pamplona, Spain

Philippe Moreau
Nantes University Hospital
Nantes, France

Contact:

Clinical Care Options Registration
https://www.clinicaloptions.com/event/IMFSatellite2017

For help with registering, call 1-855-224-2241
(9:00 a.m. - 5:00 p.m. Eastern, weekdays)

back to top

Hemophilia 2018: Current and Emerging Therapies

Friday, December 8, 2017, 12:30 p.m. - 4:30 p.m.
Georgia World Congress Center, Bldg C- Lvl 2- C202-C204

This program is sponsored by Medscape LLC and supported by Bioverativ.

Experts will explore the practical implications of the changing hemophilia treatment landscape, which includes the newly available extended half-life factor products as well as those in development, investigational nonfactor products, and gene therapy. Through case study presentation and audience response, this program, designed by National Hemophilia Foundation and Medscape, will increase clinicians' knowledge of the data and rationale for these products, and address strategies for how they may ultimately be integrated into care.

Chair:

Steven Pipe, MD
University of Michigan
Ann Arbor, MI

Speakers:

K. John Pasi
Barts and the London School of Medicine
London, United Kingdom

Michael U. Callaghan, MD
Wayne State University
Detroit, MI

Stacy E. Croteau, MD
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Boston, MA

Contact:

Haleh Kadkhoda
Medscape LLC
Phone: 215-284-6869
Email: hkadkhoda@medscape.net

back to top

Optimizing Management of Acute Lymphoblastic Leukemia: From Adolescents to Adults

Friday, December 8, 2017, 12:30 p.m. - 4:30 p.m.
Hyatt Regency Atlanta, Int'l Ballroom North

This program is sponsored by prIME Oncology and supported by Amgen and Shire.

This engaging satellite symposium is specifically designed to address educational challenges that persist for health care professionals involved in the treatment of adolescents and young adults (AYAs) and older adults with acute lymphoblastic leukemia (ALL). The audience will have the opportunity to learn from national/international experts about contemporary best practices, including principles relating to diagnosis, risk and treatment response assessment, and selection of therapy in the settings of remission induction, consolidation, maintenance, and relapsed/refractory disease. The faculty will review recent clinical trials and discuss how to effectively incorporate novel ALL therapies into treatment regimens. Interactive sessions will be interspersed between the didactic presentations on these topics to improve learner engagement and reinforce audience learning. AYAs and older adults with ALL continue to have a worse prognosis compared to pediatric patients, and this important educational activity will update learners on the latest treatment developments for these high-risk populations.

Chair:

Susan M. O'Brien, MD
UC Irvine, Chao Family Comprehensive Cancer Center
Orange, CA

Speakers:

Nicola Goekbuget, MD
Goethe University Hospital
Frankfurt, Germany

Ching-Hon Pui, MD
St. Jude Children's Research Hospital
Memphis, TN

Stephen E. Sallan, MD
Dana-Farber Cancer Institute and Boston Children's Hospital
Boston, MA

Eunice S. Wang, MD
Roswell Park Cancer Institute
Buffalo, NY

Contact:

Caroline Roberts
prIME Oncology
Phone: 404-435-7892
Email: caroline.roberts@primeoncology.org

back to top

Polycythemia Vera and Myelofibrosis: Expert Perspectives on Challenging Cases, Clinical Issues, Practice Patterns, and Emerging Treatment Options

Friday, December 8, 2017, 12:30 p.m. - 4:30 p.m.
Marriot Marquis Atlanta, Imperial A

This program is jointly provided by Postgraduate Institute for Medicine and Clinical Care Options LLC and supported by Incyte Corporation.

This symposium will provide a review of emerging data, new guidelines, and optimal treatment selection for patients with polycythemia vera (PV) and myelofibrosis (MF). You can expect an engaging symposium format that actively involves participants in the program, allowing direct interaction with experts. Participants will be presented with case examples followed by a management question. After the audience votes on the case, the panelists will review the available data along with a summary of the treatment recommendations and results of a unique online treatment decision support tool. The panel will discuss and debate each case in the symposium and will defend and provide a rationale for their individual treatment recommendations. This is a perfect opportunity to increase understanding of the latest practice-changing data and emerging novel agents/combination regimens in preparation to provide evidence-based care for your patients with PV and MF. Topics will include:

  • Distinguishing PV and MF From Reactive Conditions and Discriminating Among the MPNs
  • Aggressive PV: Characteristics, Clinical Implications, and Treatment Considerations
  • Second-line Therapies in PV: Determining the Optimal Strategy After Hydroxyurea Failure
  • Optimizing Therapeutic Strategies for Patients With MF
  • Building Better Combination Strategies in MF Treatment
  • 2018 Treatment Algorithm for PV and MF

Chair:

Srdan Verstovsek, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, TX

Speakers:

John Mascarenhas, MD
Icahn School of Medicine at Mount Sinai
New York, NY

Raajit K. Rampal, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Brady L. Stein, MD, MHS
Northwestern University Feinberg School of Medicine
Chicago, IL

Contact:

Clinical Care Options Registration
https://www.clinicaloptions.com/event/PV_MFSatellite2017

For help with registering, call 1-855-224-2241
(9:00 a.m. - 5:00 p.m. Eastern, weekdays)

back to top

Shining a Light on Benign Hematology Conditions: Focus on New Insights and Emerging Therapies

Friday, December 8, 2017, 12:30 p.m. - 4:30 p.m.
Georgia World Congress Center, Bldg C- Lvl 2- C208-C210

This program is sponsored by Medscape and supported by Rigel and Bluebird Bio.

Many hematologists/oncologists have limited experience diagnosing or managing patients with benign hematology conditions such as immune thrombocytopenia (ITP) and thalassemia. However, there have been many recent advances and emerging data regarding the treatment and ongoing management of these benign hematologic conditions. There is a need for clinicians who may encounter patients with benign hematologic disorders to develop an understanding of the management of these conditions and be aware of emerging data that can guide their treatment. The symposium will feature two in-depth didactic presentations, each focusing on a specific disorder and followed by a moderated expert exchange among the faculty. Through an interactive question and answer session and audience response, this program will increase attendee awareness and knowledge of emerging clinical data for these conditions, will increase physicians’ competence in evaluating current treatment options for patients with ITP and thalassemia, while also increasing physician confidence in treating and managing these rare and challenging hematology conditions.

Chair:

Ellis J. Neufeld, MD, PhD
St. Jude Children's Research Hospital
Memphis, TN

Speakers:

James B. Bussel, MD
Weill Cornell Medicine
New York, NY

Janet L. Kwiatkowski, MD
Children's Hospital of Philadelphia
Philadelphia, PA

Contact:

Emily S. Van Laar
Medscape
Phone: 646-465-2892
Email: evanlaar@medscape.net

back to top

Stories from the MPN Casebook: Expert Perspectives on Challenging Treatment Decisions in Polycythemia Vera and Myelofibrosis

Friday, December 8, 2017, 12:30 p.m. - 4:30 p.m.
Hyatt Regency Atlanta, Regency VI

This program is sponsored by PeerView Institute for Medical Education and supported by Incyte Corporation.

Philadelphia-chromosome negative myeloproliferative neoplasms (MPNs) are increasingly being recognized as a complex set of disorders that require nuanced approaches to disease recognition, treatment selection, and therapeutic sequencing. This change is fueled by new insights into disease biology for disorders such as polycythemia vera (PV) and myelofibrosis (MF), and the availability of novel, effective therapeutic options, including for patients who may not present with ‘classic’ disease features at baseline or at any point along the disease continuum.

PeerView will explore these exciting developments in an integrated live, on-demand educational initiative anchored by a Friday Satellite Symposium at the 2017 ASH Annual Meeting. This CME-certified activity will utilize the PeerView Live Casebook format, offering learners a collection of patient stories detailing clinical decision points in key treatment settings in PV and MF, paired with analysis of the latest evidence on disease management. The cases will also feature point-by-point illustrations of how challenging MPN presentations can be effectively managed with available options despite falling outside of standard characterizations of PV or MF. Learners will also receive case summaries as ‘point of care’ tools to use as guide for managing MPNs not corresponding to conventional clinical consensus.

Chair:

Ruben A. Mesa, MD
Mayo Clinic
Phoenix, AZ

Speakers:

Nicolaus Kröger
University Hospital Hamburg-Eppendorf
Hamburg, Germany

Robyn M. Scherber, MD
Oregon Health and Sciences University
Portland, OR

Francesco Passamonti, MD
University of Insubria
Varese, Italy

Contact:

Cassie Rametta
PeerView Institute for Medical Education
Phone: 1-877-833-6141
Email: live@peerview.com

back to top

Targeting With FLT3 Tyrosine Kinase Inhibitors in Acute Myeloid Leukemia

Friday, December 8, 2017, 12:30 p.m. - 4:30 p.m.
Georgia World Congress Center, Bldg B- Lvl 4- B401-B402

This program is sponsored by Hemedicus, Inc. and supported by Daiichi Sankyo, Inc. and Novartis Pharmaceuticals.

Over the years, advancements in understanding acute myeloid leukemia (AML) and its treatment have been made. However, AML is still a disease with a variable prognosis and high mortality rate. Notably, the five-year survival of AML is only 26% and approximately 20% to 30% of patients have FLT3-mutated AML. It is, therefore, not surprising that treating patients with AML remains a daunting task. Therapeutic failure and recurrent disease are common, necessitating more effective and less toxic treatments and improved biomarkers to inform treatment decisions. Ongoing efforts are directed at integrating FLT3 tyrosine kinase inhibitors in AML treatment paradigms. This symposium will assist physicians as they incorporate the most recent advances in FLT3 inhibition into their practice of medicine.

Chair:

Richard M. Stone, MD
Harvard Medical School
Boston, MA

Speakers:

Keith Pratz, MD
Johns Hopkins University School of Medicine
Baltimore, MD

Marlise R. Luskin, MD
Dana-Farber Cancer Institute
Boston, MA

Hartmut Dohner, MD
Universitätsklinikum Ulm
Ulm, Germany

Jacob M. Rowe, MD
Shaare Zedek Medical Center
Jerusalem, Israel

Contact:

Robin Simak
Hemedicus, Inc
Phone: 201-666-4700
Email: rsimak@hemedicus.com

back to top

Test Driving CARs: Optimizing Outcomes

Friday, December 8, 2017, 12:30 p.m. - 4:30 p.m.
Georgia World Congress Center, Bldg C- Lvl 1- C108-C109

This program is sponsored by Medscape and supported by Kite Pharma and Novartis Pharmaceuticals Corporation.

This satellite symposium is designed to familiarize clinicians with the efficacy data and management concerns regarding CAR T-cell therapy in order to prepare clinicians to integrate this emerging strategy into clinical practice when available. Attendees of the live symposium interact with a panel of expert faculty by participating in a question-and-answer period, case dialogue, and polling using an audience response system. Live engagement allows for the exchange of ideas, deepening participant involvement, and enabling attendees to drive the discussion according to their own clinical challenges.

Chair:

Frederick L. Locke, MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL

Speakers:

Sattva S. Neelapu, MD
The University of Texas MD Anderson Cancer Center
Houston, TX

Rebecca Gardner, MD
Seattle Children's Hospital
Seattle, WA

Contact:

Emily S. Van Laar
Medscape
Phone: 646-465-2892
Email: evanlaar@medscape.net

back to top